ABSTRACT
White matter hyperintensities (WMHs) on T2-weighted images are radiological signs of cerebral small vessel disease. As their total volume is variably associated with cognition, a new approach that integrates multiple radiological criteria is warranted. Location may matter, as periventricular WMHs have been shown to be associated with cognitive impairments. WMHs that appear as hypointense in T1-weighted images (T1w) may also indicate the most severe component of WMHs. We developed an automatic method that classifies WMHs into four categories (periventricular/deep and T1w-hypointense/nonT1w-hypointense) using MRI data from 684 community-dwelling older adults from the Whitehall II study. To test if location and intensity information can impact cognition, we derived two general linear models using either overall or subdivided volumes. Results showed that periventricular T1w-hypointense WMHs were significantly associated with poorer performance in several cognitive tests. We found no association between total WMH volume and cognition. These findings suggest that classifying WMHs according to both location and intensity in T1w adds value over and above total WMH volume.
HIGHLIGHTS
Heterogeneous measures of WMHs are used in research and clinical practice.
Location and image intensity should be considered in the assessment of WMHs.
T1-hypointense WMHs were found to be associated with poorer cognitive performance.
Sub-classes of WMHs provide promising results for translation into the clinic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the UK Medical Research Council (MRC) grants “Dementias Platform UK” (MR/L023784/2) and “Predicting MRI abnormalities with longitudinal data of the Whitehall II Substudy” (UK Medical Research Council: G1001354, PI: KPE), and by the HDH Wills 1965 Charitable Trust (Nr: 1117747, PI: KPE). This study was also supported by the Wellcome Centre for Integrative Neuroimaging, which has core funding from the Wellcome Trust (203139/Z/16/Z). C.E.M., N.F. and L.G. were supported by the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centres (BRC), a partnership between Oxford Health NHS Foundation Trust and the University of Oxford. L.G. was also supported by the Oxford Parkinson’s Disease Centre (Parkinson’s UK Monument Discovery Award) and the MRC Dementias Platform UK. E.Zs, K.P.E. and S.S. were supported by the European Union’s Horizon 2020 programme “Lifebrain” (732592). S.S. was also supported by an Alzheimer’s Society Junior Research Fellowship (Grant ref: 441). V.S. and M.J. were supported by the Wellcome Centre for Integrative Neuroimaging. M.J. was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), and this research was funded by the Wellcome Trust (215573/Z/19/Z). A.S.-M. receives research support from the US National Institutes of Health (R01AG056477). M.K. was supported by NordForsk, the UK Medical Research Council (MRC S011676), the Academy of Finland (311492), and the US National Institutes on Aging (NIA R01AG056477, RF1AG062553).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the University of Oxford Central University Research Ethics Committee, and the UCL Medical School Committee on the Ethics of Human Research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study follows MRC data sharing policies (https://www.mrc.ac.uk/research/policies-and-guidance-for-researchers/data-sharing/). Data will be accessible via the Dementias Platform UK (https://portal.dementiasplatform.uk/) after 2020. The extended ventricle mask described in the methods section and the scripts created for images post-processing are already publicly available (https://git.fmrib.ox.ac.uk/ludovica/wmh-sub-classes).
